دورية أكاديمية

Treatment preference and quality of life impact: Ravulizumab vs eculizumab for atypical hemolytic uremic syndrome

التفاصيل البيبلوغرافية
العنوان: Treatment preference and quality of life impact: Ravulizumab vs eculizumab for atypical hemolytic uremic syndrome
المؤلفون: Mauch, Teri J, Chladek, Michael R, Cataland, Spero, Chaturvedi, Shruti, Dixon, Bradley P, Garlo, Katherine, Gasteyger, Christoph, Java, Anuja, Leguizamo, Jorge, Lloyd-Price, Lucy, Pham, Tan P, Symonds, Tara, Tomazos, Ioannis, Wang, Yan
المصدر: 2020-Current year OA Pubs
بيانات النشر: Digital Commons@Becker
سنة النشر: 2023
المجموعة: Washington University School of Medicine: Digital Commons@Becker
مصطلحات موضوعية: Adult, Humans, Child, Middle Aged, Atypical Hemolytic Uremic Syndrome, Quality of Life, Antibodies, Monoclonal, Humanized, Complement Inactivating Agents, ICTS (Institute of Clinical and Translational Sciences), Medicine and Health Sciences
نوع الوثيقة: text
وصف الملف: application/pdf
اللغة: unknown
العلاقة: https://digitalcommons.wustl.edu/oa_4/2212Test; https://digitalcommons.wustl.edu/context/oa_4/article/3209/viewcontent/Treatment_preference_and_quality.pdfTest
DOI: 10.57264/cer-2023-0036
الإتاحة: https://doi.org/10.57264/cer-2023-0036Test
https://digitalcommons.wustl.edu/oa_4/2212Test
https://digitalcommons.wustl.edu/context/oa_4/article/3209/viewcontent/Treatment_preference_and_quality.pdfTest
رقم الانضمام: edsbas.28E23C1C
قاعدة البيانات: BASE